Privium Fund Management B.V. Sells 163,023 Shares of uniQure N.V. (NASDAQ:QURE)

Key Points

• Privium Fund Management B.V. reduced its stake in uniQure N.V. by 22.0%, now holding 579,139 shares, making it the 15th largest position in their portfolio.
• Several institutional investors, including Avoro Capital Advisors LLC and Point72 Asset Management L.P., significantly increased their stakes in uniQure, with Point72 boosting its position by 81.3%.
• uniQure reported quarterly earnings with an EPS of ($0.69), surpassing estimates, and analysts currently have a consensus rating of "Moderate Buy" with an average target price of $36.55.

Privium Fund Management B.V. cut its holdings in uniQure N.V. (NASDAQ:QURE - Free Report) by 22.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 579,139 shares of the biotechnology company's stock after selling 163,023 shares during the quarter. uniQure comprises about 1.6% of Privium Fund Management B.V.'s investment portfolio, making the stock its 15th biggest holding. Privium Fund Management B.V. owned 1.06% of uniQure worth $6,139,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of QURE. JPMorgan Chase & Co. raised its holdings in uniQure by 14.7% during the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 58,246 shares during the period. Alliancebernstein L.P. raised its holdings in uniQure by 14.2% during the 4th quarter. Alliancebernstein L.P. now owns 203,919 shares of the biotechnology company's stock worth $3,601,000 after buying an additional 25,319 shares during the period. Franklin Resources Inc. raised its holdings in uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after buying an additional 494,726 shares during the period. Headlands Technologies LLC acquired a new stake in uniQure during the 4th quarter worth about $326,000. Finally, Geode Capital Management LLC raised its holdings in uniQure by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock worth $9,198,000 after buying an additional 11,951 shares during the period. 78.83% of the stock is currently owned by institutional investors.

Insider Transactions at uniQure

In other news, Director Rachelle Suzanne Jacques sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director owned 28,346 shares in the company, valued at $409,599.70. This represents a 6.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jack Kaye sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $295,343.55. This represents a 9.37% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,144 shares of company stock worth $322,426. Corporate insiders own 4.79% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on QURE. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Cantor Fitzgerald set a $47.00 target price on uniQure in a report on Wednesday, July 30th. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Chardan Capital lowered their price target on uniQure from $38.00 to $35.00 and set a "buy" rating for the company in a research note on Tuesday, July 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, uniQure has a consensus rating of "Moderate Buy" and a consensus target price of $36.55.

uniQure Stock Down 3.9%

NASDAQ QURE traded down $0.55 during trading on Wednesday, hitting $13.45. The stock had a trading volume of 405,698 shares, compared to its average volume of 1,414,446. The company has a market capitalization of $738.02 million, a PE ratio of -3.43 and a beta of 0.11. The company's 50-day moving average price is $14.78 and its two-hundred day moving average price is $13.68. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure N.V. has a 12 month low of $4.45 and a 12 month high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. As a group, sell-side analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.